Drug Profile
PPI 1011
Alternative Names: Ethanolamine plasmalogen precursor - Phenomenome Discoveries; Ether glycerophosphoethanolamine lipid precursor - Phenomenome Discoveries; Ether lipid precursor - Phenomenome Discoveries; PlsEtn precursor - Phenomenome Discoveries; PPI-1011Latest Information Update: 03 Aug 2023
Price :
$50
*
At a glance
- Originator Phenomenome Discoveries
- Developer GraySpace Therapeutics; Phenomenome Discoveries
- Class 1 ring heterocyclic compounds; Esters; Ethers; Omega 3 fatty acids; Plasmalogens
- Mechanism of Action Plasmalogen replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Rhizomelic chondrodysplasia punctata
- Preclinical Alzheimer's disease; Dyskinesias; Parkinson's disease
- Discontinued Pelizaeus-Merzbacher disease
Most Recent Events
- 29 May 2023 Phase-I clinical trials in Rhizomelic chondrodysplasia punctata in Canada (PO) (NCT05969977)
- 03 Jan 2023 Chemical structure information added
- 28 Dec 2022 PPI 1011 is still in preclinical trials in Alzheimer's disease in Canada (PO) as of December 2022 (GraySpace Therapeutics website, December 2022)